FDA Approves Two Immunotherapies for Advanced Melanoma
Metastatic melanoma patients have received very good news with the FDA’s approval of two important new immune-boosting therapies.
FDA Approves Second Targeted Combination Therapy for Advanced Melanoma
The US Food and Drug Administration (FDA) approved the combination targeted therapy vemurafenib-cobimetinib (Zelboraf-Cotellic) for about half of all patients with Stage IV melanoma that is inoperable or has metastasized throughout the body.
In the Spotlight